Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trimebutine - Labopharm

Drug Profile

Trimebutine - Labopharm

Alternative Names: Modulon SR; Trimebutine maleate

Latest Information Update: 10 Oct 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Axcan Pharma; Labopharm
  • Developer Labopharm
  • Class Antispasmodics; Benzoic acids; Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 01 Sep 2004 Discontinued - Phase-I for Irritable bowel syndrome in Canada (PO)
  • 26 Sep 2002 Phase-I clinical trials in Irritable bowel syndrome in Canada (unspecified route)
  • 24 Jul 2002 Labopharm and Axcan have signed a letter of intent on a global licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top